Dec 6, 2018
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients...
145
top of page
Posts Archive
bottom of page